OTCMKTS:BICX BioCorRx (BICX) Stock Price, News & Analysis $0.35 +0.04 (+11.39%) (As of 05:36 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest About BioCorRx Stock (OTCMKTS:BICX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BioCorRx alerts:Sign Up Key Stats Today's Range$0.31▼$0.3550-Day Range$0.30▼$0.5052-Week Range$0.28▼$1.50Volume1,151 shsAverage Volume1,945 shsMarket Capitalization$4.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition. The company is also developing BICX101, an injectable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers, independent licensed clinics, and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.Read More… Financial Prophecy (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Receive BICX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioCorRx and its competitors with MarketBeat's FREE daily newsletter. Email Address BICX Stock News HeadlinesCritical Analysis: Concentra Group Holdings Parent (NYSE:CON) and BioCorRx (OTCMKTS:BICX)November 13 at 2:55 AM | americanbankingnews.comBioCorRx (OTCMKTS:BICX) vs. Concentra Group Holdings Parent (NYSE:CON) Head-To-Head ComparisonNovember 12 at 2:05 AM | americanbankingnews.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 14, 2024 | Crypto 101 Media (Ad)La Rosa Holdings Corp. secures new financing, reshuffles leadershipOctober 6, 2024 | investing.comBioCorRx Inc: BioCorRx Reports Business Update for the Second Quarter of 2024August 16, 2024 | finanznachrichten.deBioCorRx Reports Business Update for the Second Quarter of 2024August 15, 2024 | globenewswire.comBioCorRx Reports Business Update for the First Quarter of 2024May 16, 2024 | finance.yahoo.comBioCorRx Inc. (BICX)April 18, 2024 | finance.yahoo.comSee More Headlines BICX Stock Analysis - Frequently Asked Questions How have BICX shares performed this year? BioCorRx's stock was trading at $0.78 on January 1st, 2024. Since then, BICX stock has decreased by 55.7% and is now trading at $0.3453. View the best growth stocks for 2024 here. How were BioCorRx's earnings last quarter? BioCorRx Inc. (OTCMKTS:BICX) posted its earnings results on Thursday, November, 17th. The company reported ($0.02) earnings per share for the quarter. The firm had revenue of $0.17 million for the quarter. How do I buy shares of BioCorRx? Shares of BICX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BioCorRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioCorRx investors own include PlayAGS (AGS), Ashford Hospitality Trust (AHT), Peabody Energy (BTU), Mondi (MNDI), Assertio (ASRT), Astronics (ATRO) and CONSOL Coal Resources (CCR). Company Calendar Last Earnings11/17/2016Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Specialty outpatient clinics, not elsewhere classified Sub-IndustryHealthcare Current SymbolOTCMKTS:BICX CUSIPN/A CIK1443863 Webwww.biocorrx.com Phone(714) 462-4880FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,770,000.00 Net Margins-11,600.00% Pretax Margin-11,637.84% Return on EquityN/A Return on Assets-998.72% Debt Debt-to-Equity RatioN/A Current Ratio0.02 Quick Ratio0.02 Sales & Book Value Annual Sales$90,000.00 Price / Sales47.97 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-0.30Miscellaneous Outstanding Shares12,504,000Free Float9,828,000Market Cap$4.32 million OptionableNot Optionable Beta0.61 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (OTCMKTS:BICX) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you wa...Porter & Company | SponsoredElon Musk’s $30 Billion Trump Bet Pays Off—What’s Next?Elon Musk bet big on Trump's victory, and that gamble has already added over $30 billion to his net worth in a...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCorRx Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCorRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.